Working… Menu

Neoadjuvant Pemetrexed, Carboplatin and Bevacizumab in Unresectable, Locally Advanced Lung Adenocarcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01588704
Recruitment Status : Completed
First Posted : May 1, 2012
Last Update Posted : January 22, 2015
Information provided by (Responsible Party):
Si-Yu Wang, Sun Yat-sen University

Brief Summary:
The prognosis of patients with unresectable, locally advanced non-small cell lung cancer (NSCLC) is poor. Chemoradiotherapy is the main treatment modality for this disease. The newer drug regimens can be expected to improve survival in this subset of NSCLC patients. Modern targeted therapies have enhanced the outcomes of lung cancer treatment, especially for advanced NSCLC. Among the targeted approaches for the inhibition of angiogenesis is bevacizumab, a monoclonal antibody that represses vascular endothelial growth factor (VEGF). Bevacizumab in combination with platinum-based chemotherapy used as neoadjuvant chemotherapy may change the previous treatment modality. It allows some lung cancer patients to be downstaged to surgery rather than radiotherapy. Thus, survival of these patients may be improved.

Condition or disease Intervention/treatment Phase
Lung Cancer Drug: Neoadjuvant Bevacizumab Phase 2

Detailed Description:
This trial investigates the role of neoadjuvant pemetrexed, carboplatin and bevacizumab in unresectable, locally advanced lung adenocarcinoma.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 42 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study of Neoadjuvant Pemetrexed, Carboplatin and Bevacizumab in Unresectable, Locally Advanced Lung Adenocarcinoma
Study Start Date : April 2012
Actual Primary Completion Date : January 2014
Actual Study Completion Date : April 2014

Arm Intervention/treatment
Experimental: Neoadjuvant Bevacizumab
Four cycles of neoadjuvant chemotherapy with pemetrexed, carboplatin and bevacizumab.
Drug: Neoadjuvant Bevacizumab
Neoadjuvant Pemetrexed, Carboplatin and Bevacizumab followed by surgical resection
Other Names:
  • Pemetrexed (Alimta)
  • Bevacizumab (Avastin)

Primary Outcome Measures :
  1. Resectability rate [ Time Frame: 3 months ]

Secondary Outcome Measures :
  1. Number of participants with perioperative complications [ Time Frame: 4 months ]
  2. Disease-free survival [ Time Frame: 2 years ]
  3. Overall survival [ Time Frame: 2 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed unresectable, locally advanced (III A (bulky N2), III B) lung adenocarcinoma
  • No previous chemotherapy, radiotherapy, surgery or biological therapy for lung cancer
  • Adequate organ and bone marrow function

Exclusion Criteria:

  • Prior chemotherapy or radiation therapy for NSCLC
  • Prior treatment with bevacizumab or other agents specifically targeting vascular endothelial growth factor (VEGF)
  • Patients with known hypersensitivity to other recombinant human antibodies
  • History of stroke or transient ischemic attack (TIA).
  • History of myocardial infarction or unstable angina within the past 12 months.
  • Other serious illness or medical condition including unstable cardiac disease requiring treatment, history of significant neurologic or psychiatric disorders (including psychotic disorders, dementia, or seizures), symptomatic diverticulitis, or active uncontrolled infection.
  • Women who are pregnant or breast-feeding

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01588704

Layout table for location information
China, Guangdong
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China, 510060
Sponsors and Collaborators
Si-Yu Wang
Layout table for investigator information
Principal Investigator: Si-Yu Wang, Doctor Sun Yat-sen University
Layout table for additonal information
Responsible Party: Si-Yu Wang, Professor, Sun Yat-sen University Identifier: NCT01588704    
Other Study ID Numbers: GASTO1001
wsy002 ( Other Identifier: Guangdong Province Association Study of Thoracic Oncology )
First Posted: May 1, 2012    Key Record Dates
Last Update Posted: January 22, 2015
Last Verified: January 2015
Keywords provided by Si-Yu Wang, Sun Yat-sen University:
lung cancer
lung adenocarcinoma
adjuvant chemotherapy
surgical resection rate
Additional relevant MeSH terms:
Layout table for MeSH terms
Adenocarcinoma of Lung
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Antineoplastic Agents, Immunological
Antineoplastic Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Folic Acid Antagonists
Nucleic Acid Synthesis Inhibitors